Ovarian EndometriomaNCT05357924
Evaluating Ovarian Reserve After Conventional Laparoscopy Versus Robotic Surgery for Bilateral Endometrioma
A study testing robotic-assisted laparoscopy and Conventional laparoscopy in people with Ovarian Endometrioma and Ovarian Endometriosis, run by Medical University of Vienna at 1 site in Austria.
Trial summary
The aim of this study is to perform a randomized study investigating AMH recovery comparing robot-assisted laparoscopy and conventional laparoscopy in patients with bilateral ovarian endometrioma. Read more about this study
- Who is it for?
- Ages 18 to 45 years, women only
- Conditions the study is for
- Ovarian Endometrioma, Ovarian Endometriosis
- What is being tested?
- robotic-assisted laparoscopy and Conventional laparoscopy
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 104 participants
- Where
- 1 siteAustria
- Study dates
- 19 Apr 2022to 31 Dec 2023
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Bilateral endometrioma
- Surgical endometriosis resection is planned
- sAMH > 1.0 ng/ml
Who cannot join
- History of malignant diseases
- History of adnexal surgery
- Subject is unable or unwilling to participate
- Postmenopausal women
Trial locations and contacts
1 site in 1 country.
Austria1 site, 1 recruiting
- Recruiting
Medical University of Vienna
Vienna, 1090
Christine Bekos, 004369913536030, christine.bekos@meduniwien.ac.at
Rene Wenzl
About this study
Official title: Evaluating Ovarian Reserve After Conventional Laparoscopy Versus Robotic Surgery for Bilateral Endometrioma: a Randomized Controlled Trial.
The aim of this study is to perform a randomized study investigating AMH recovery comparing robot-assisted laparoscopy and conventional laparoscopy in patients with bilateral ovarian endometrioma. It is hypothesized that in patients with endometriomas, a robot-assisted approach may provide improved instrument navigation resulting in more precise dissection and therefore removal of less healthy ovarian tissue compared to conventional laparoscopy. AMH is the most widely used parameter for predicting functional ovarian reserve. Postoperative AMH levels were associated with the number of follicles in specimens due to the removal of ovarian cortex during surgery . Furthermore, the reduction in AMH level after surgery is higher in bilateral endometrioma.
The investigators hypothesize, on the basis of Lee at al., 2020, that patients with bilateral endometrioma will have significantly higher AMH levels 6 months after robot-assisted laparoscopy than patients who were treated with conventional laparoscopy.
Read more
Therefore, the primary outcome is postoperative serum AMH level recovery in patients undergoing conventional laparoscopy versus robot-assisted laparoscopy.
Aims: The aim of this study is to investigate postoperative differences in ovarian reserve differing between robot-assisted laparoscopy compared to conventional laparoscopy in patients with bilaterial ovarian endometrioma by comparing serum AMH (sAMH) level recovery.
Study population: The study population will consist of women aged between 18 and 45 years who are referred to our gynecologic outpatient clinic due to bilateral endometrioma. Women with an indication for surgery can be included in this trial.
Methods: Laparoscopic-assisted resection of endometriosis will be performed using up to four 5-mm ports, including an umbilical port and additional ports as dictated by each individual surgery. The robotic-assisted resection of endometriosis will be performed using the da Vinci Surgical System Si (Intuitive Surgical) using up to five ports as needed. Superficial and deep endometriosis resection will be performed in the usual standard fashion. Histological confirmation of endometriosis will be performed. The primary outcome is postoperative serum AMH (sAMH) level recovery. This will be evaluated 6 months after surgery.
Read the detailed description
Experimental Plan
Study design This trial is a prospective, randomized-controlled study investigating postoperative differences in ovarian reserve differing between robot-assisted laparoscopy compared to conventional laparoscopy in patients with bilaterial ovarian endometrioma by comparing serum AMH (sAMH) level recovery. Postoperative follow-up will take place after 6 months. All women referred to our department for endometrioma will undergo clinical examination by a senior surgeon experienced in endometriosis as well as ultrasound. All patients with bilateral endometrioma will be included. Complementary examinations, such as cystoscopy or renal sonography will be performed in women with suspected involvement of urinary tract.
In women with pregnancy intention and endometrioma, an exhaustive assessment of the disease will systematically be performed before deciding between primary surgery and primary assisted reproductive techniques.
Gynecological examination will be performed at each visit. Ovarian reserve will be evaluated using antral follicle count (AFC) via transvaginal sonography, anti-Mullerian hormone (AMH), follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels and ovarian volume.
Follicle number will be evaluated by pathologists in the histologic tissue sections.
Furthermore, subjective outcome will be assessed with standardized questionnaires.
Study setting This study will be conducted at the gynecologic outpatient clinic (Division of General Gynecology and Gynecologic Oncology, Department of Obstetrics and Gynecology, Medical University of Vienna). Enrollment, treatment and data collection will be standardized by all sites according to the approved study protocol.
Participants and recruitment The study population will consist of women aged between 18 and 45 years who are referred to our gynecologic outpatient clinic due to endometrioma. Women with bilateral endometrioma and an indication for surgery can be included in this trial.
Intervention Laparoscopic-assisted cystectomy of endometrioma will be performed using up to four 5-mm ports, including an umbilical port and additional ports as dictated by each individual surgery. The robotic-assisted resection of endometriosis will be performed using the da Vinci Surgical System Si (Intuitive Surgical) using up to five ports as needed. An umbilical port was placed for the laparoscope (10/12 mm), a 5-mm port for the assistant, and two or three ports (5/8 mm) for the robotic arms. Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. A cystoscopy will be performed when deemed appropriate by the surgeon. If bowel resection and re-anastomosis are necessary this will be performed together with a General Surgeon.
Participating surgeons will be defined as high-volume surgeons in endometriosis surgery and will also be part of the endometriosis core team.
Histological confirmation of endometriosis will be performed.
Postoperative Management: The patients are instructed to rest for 2 weeks after the operation (not to work, do sport, do the cleaning, and carry more than five kilos). They are allowed to return to work after 2 weeks and to take part in sports or have intercourse after 6 weeks. Follow-up visits are scheduled after 6 months in our outpatient clinic due to our study protocol.
For the postoperative medical treatment of endometriosis, combined oral contraceptive, a GnRH agonist or Dienogest will be administered to all patients who do not desire pregnancy. Patients desiring pregnancy will either be advised to attempt spontaneous conception or will be sent to our in-house ART department depending on their age, disease extent, preoperative AMH levels and male factors.
Data collection At baseline, the following data will be collected: demographics and medical history data (age, body mass index, parity, menopausal and hormone therapy status, current smoking, previous adnexal surgery, and medical comorbidities (diabetes mellitus, connective tissue disorders)). Previous endometriosis-specific treatments and responses will be assessed. Patients will be asked to complete the Endometriosis Health Profile (EHP) EHP-30 25. A gynecological examination will be performed at each visit. Ovarian reserve will be evaluated using antral follicle count (AFC), anti-Mullerian hormone (AMH), follicle-stimulating hormone (FSH), and luteinizing hormone (LH) levels, and ovarian volume.
Preferentially, LH and FSH will be evaluated in the first 2 to 5 days of the menstrual cycle.
The patients will be asked to rate their satisfaction with the appearance of their scars on a 10-point Likert scale (with 1 being very unsatisfied and 10 being very satisfied).
- Conditions
- Ovarian Endometrioma, Ovarian Endometriosis
- Being tested
- robotic-assisted laparoscopy, Conventional laparoscopy
- Medical subject headings
- Endometriosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
robotic-assisted laparoscopyProcedure or surgery
Also called DaVinci laparoscopy
Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. Cystoscopy will be performed when deemed appropriate by the surgeon. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon.
Conventional laparoscopyProcedure or surgery
Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. Cystoscopy will be performed when deemed appropriate by the surgeon. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon.
| Study group | Role | What they receive |
|---|---|---|
| robotic-assisted laparoscopy | Active comparator | The robotic-assisted resection of endometriosis will be performed using the da Vinci Surgical System Si (Intuitive Surgical) using up to five ports as needed. An umbilical port was placed for the laparoscope (10/12 mm), a 5-mm port for the assistant, and two to three ports (5/8 mm) for the robotic arms. Receives: Procedure: robotic-assisted laparoscopy |
| conventional laparoscopy | Active comparator | Laparoscopic-assisted cystectomy of endometrioma will be performed using up to four 5-mm ports, including an umbilical port and additional ports as dictated by each individual surgery. Receives: Procedure: Conventional laparoscopy |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in serum AMH (sAMH) from baseline to 6 months after the operation
postoperative sAMH (6 months after the operation) compared to preoperative sAMH
Measured: 6 months after the operation
Secondary outcomes (13)
Change in antral follicle count (AFC) from baseline to 6 months after the operation
antral follicle count (AFC) measured via transvaginal sonography
Measured: 6 months after the operation
change in ovarian volume from baseline to 6 months after the operation
ovarian volume measured via transvaginal sonography (preoperative ovarian volume - endometrioma volume versus postoperative ovarian volume)
Measured: 6 months after the operation
change in follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from baseline to 6 months after the operation
postoperative FSH and LH(6 months after the operation) compared to preoperative FSH and LH (both times measured within the first 2-5 days of menstrual cycle)
Measured: 6 months after the operation
rate of intraoperative adverse events
rate of intraoperative adverse events (bladder injury, bowel injury, ureteral obstruction, massive bleeding)
Measured: 1 day
rate of postoperative adverse events
rate of postoperative adverse events related to surgery (classified using Clavien Dindo classification)
Measured: 4 weeks
operation time
operation time in minutes
Measured: 1 day
length of hospitalization (following the operation)
length of hospitalization in days
Measured: 2 weeks
blood loss
change of hemoglobin levels 24 hours after surgery
Measured: 1 day
laparotomic conversion rate
laparotomic conversion rate
Measured: 1 day
follicle number in the histologic tissue sections
follicle number in the histologic tissue sections
Measured: 1 day
change of the Endometriosis Health Profile (EHP) EHP-30 from baseline to 6 months after the operation
questionnaires: the Endometriosis Health Profile (EHP) EHP-30 (preoperative versus 6 months after the operation
Measured: 6 months after the operation
10-point Likert scale for cosmetic satisfaction
questionnaires: 10-point Likert scale for cosmetic satisfaction
Measured: 6 months after the operation
Disease recurrence rate up to 12 months after surgery
Endometriosis recurrence can have different levels: symptoms recurrence based on patient history (VAS pain score ≥ 5), but no proof of recurrence by imaging and/or surgery; endometriosis recurrence based on non-invasive imaging in patients with or without symptoms; recurrence of histologically proven endometriosis: when the patient is re-operated, endometriosis is visually observed and confirmed histologically.
Measured: 12 months after the operation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 May 2022
- Study start19 Apr 2022
- Primary completion31 Dec 2023 (estimated)
- Study completion31 Dec 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ovarian EndometriomaStudies of the same condition, open and under way.
- More trials run by Medical University of ViennaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 104 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Medical University of Vienna
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Christine Bekos, Medical University of Vienna
- Investigators
- Rene Wenzl, Study director, Medical University of Vienna, Department of Obstetrics and Gynecology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05357924
- Sponsor's protocol ID
- AMH robotic LSK
- Status last verified
- Jun 2022
- First submitted
- 27 Apr 2022
- Last updated
- 8 Jun 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Jun 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluating Ovarian Reserve After Conventional Laparoscopy Versus Robotic Surgery for Bilateral Endometrioma: a Randomized Controlled Trial.
- ClinicalTrials.gov ID
- NCT05357924
- Acronym / sponsor ID
- AMH robotic LSK
- Conditions
- Ovarian Endometrioma, Ovarian Endometriosis
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 104 participants (estimated)
- Lead sponsor
- Medical University of ViennaUniversity, hospital or other
- Study start
- 19 Apr 2022 (actual)
- Primary completion
- 31 Dec 2023 (estimated)
- Study completion
- 31 Dec 2023 (estimated)
- First posted
- 3 May 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to perform a randomized study investigating AMH recovery comparing robot-assisted laparoscopy and conventional laparoscopy in patients with bilateral ovarian endometrioma. It is hypothesized that in patients with endometriomas, a robot-assisted approach may provide improved instrument navigation resulting in more precise dissection and therefore removal of less healthy ovarian tissue compared to conventional laparoscopy. AMH is the most widely used parameter for predicting functional ovarian reserve. Postoperative AMH levels were associated with the number of follicles in specimens due to the removal of ovarian cortex during surgery . Furthermore, the reduction in AMH level after surgery is higher in bilateral endometrioma.
The investigators hypothesize, on the basis of Lee at al., 2020, that patients with bilateral endometrioma will have significantly higher AMH levels 6 months after robot-assisted laparoscopy than patients who were treated with conventional laparoscopy.
Therefore, the primary outcome is postoperative serum AMH level recovery in patients undergoing conventional laparoscopy versus robot-assisted laparoscopy.
Aims: The aim of this study is to investigate postoperative differences in ovarian reserve differing between robot-assisted laparoscopy compared to conventional laparoscopy in patients with bilaterial ovarian endometrioma by comparing serum AMH (sAMH) level recovery.
Study population: The study population will consist of women aged between 18 and 45 years who are referred to our gynecologic outpatient clinic due to bilateral endometrioma. Women with an indication for surgery can be included in this trial.
Methods: Laparoscopic-assisted resection of endometriosis will be performed using up to four 5-mm ports, including an umbilical port and additional ports as dictated by each individual surgery. The robotic-assisted resection of endometriosis will be performed using the da Vinci Surgical System Si (Intuitive Surgical) using up to five ports as needed. Superficial and deep endometriosis resection will be performed in the usual standard fashion. Histological confirmation of endometriosis will be performed. The primary outcome is postoperative serum AMH (sAMH) level recovery. This will be evaluated 6 months after surgery.
Detailed description
Experimental Plan
Study design This trial is a prospective, randomized-controlled study investigating postoperative differences in ovarian reserve differing between robot-assisted laparoscopy compared to conventional laparoscopy in patients with bilaterial ovarian endometrioma by comparing serum AMH (sAMH) level recovery. Postoperative follow-up will take place after 6 months. All women referred to our department for endometrioma will undergo clinical examination by a senior surgeon experienced in endometriosis as well as ultrasound. All patients with bilateral endometrioma will be included. Complementary examinations, such as cystoscopy or renal sonography will be performed in women with suspected involvement of urinary tract.
In women with pregnancy intention and endometrioma, an exhaustive assessment of the disease will systematically be performed before deciding between primary surgery and primary assisted reproductive techniques.
Gynecological examination will be performed at each visit. Ovarian reserve will be evaluated using antral follicle count (AFC) via transvaginal sonography, anti-Mullerian hormone (AMH), follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels and ovarian volume.
Follicle number will be evaluated by pathologists in the histologic tissue sections.
Furthermore, subjective outcome will be assessed with standardized questionnaires.
Study setting This study will be conducted at the gynecologic outpatient clinic (Division of General Gynecology and Gynecologic Oncology, Department of Obstetrics and Gynecology, Medical University of Vienna). Enrollment, treatment and data collection will be standardized by all sites according to the approved study protocol.
Participants and recruitment The study population will consist of women aged between 18 and 45 years who are referred to our gynecologic outpatient clinic due to endometrioma. Women with bilateral endometrioma and an indication for surgery can be included in this trial.
Intervention Laparoscopic-assisted cystectomy of endometrioma will be performed using up to four 5-mm ports, including an umbilical port and additional ports as dictated by each individual surgery. The robotic-assisted resection of endometriosis will be performed using the da Vinci Surgical System Si (Intuitive Surgical) using up to five ports as needed. An umbilical port was placed for the laparoscope (10/12 mm), a 5-mm port for the assistant, and two or three ports (5/8 mm) for the robotic arms. Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. A cystoscopy will be performed when deemed appropriate by the surgeon. If bowel resection and re-anastomosis are necessary this will be performed together with a General Surgeon.
Participating surgeons will be defined as high-volume surgeons in endometriosis surgery and will also be part of the endometriosis core team.
Histological confirmation of endometriosis will be performed.
Postoperative Management: The patients are instructed to rest for 2 weeks after the operation (not to work, do sport, do the cleaning, and carry more than five kilos). They are allowed to return to work after 2 weeks and to take part in sports or have intercourse after 6 weeks. Follow-up visits are scheduled after 6 months in our outpatient clinic due to our study protocol.
For the postoperative medical treatment of endometriosis, combined oral contraceptive, a GnRH agonist or Dienogest will be administered to all patients who do not desire pregnancy. Patients desiring pregnancy will either be advised to attempt spontaneous conception or will be sent to our in-house ART department depending on their age, disease extent, preoperative AMH levels and male factors.
Data collection At baseline, the following data will be collected: demographics and medical history data (age, body mass index, parity, menopausal and hormone therapy status, current smoking, previous adnexal surgery, and medical comorbidities (diabetes mellitus, connective tissue disorders)). Previous endometriosis-specific treatments and responses will be assessed. Patients will be asked to complete the Endometriosis Health Profile (EHP) EHP-30 25. A gynecological examination will be performed at each visit. Ovarian reserve will be evaluated using antral follicle count (AFC), anti-Mullerian hormone (AMH), follicle-stimulating hormone (FSH), and luteinizing hormone (LH) levels, and ovarian volume.
Preferentially, LH and FSH will be evaluated in the first 2 to 5 days of the menstrual cycle.
The patients will be asked to rate their satisfaction with the appearance of their scars on a 10-point Likert scale (with 1 being very unsatisfied and 10 being very satisfied).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| robotic-assisted laparoscopy | Active comparator | Procedure: robotic-assisted laparoscopyThe robotic-assisted resection of endometriosis will be performed using the da Vinci Surgical System Si (Intuitive Surgical) using up to five ports as needed. An umbilical port was placed for the laparoscope (10/12 mm), a 5-mm port for the assistant, and two to three ports (5/8 mm) for the robotic arms. |
| conventional laparoscopy | Active comparator | Procedure: Conventional laparoscopyLaparoscopic-assisted cystectomy of endometrioma will be performed using up to four 5-mm ports, including an umbilical port and additional ports as dictated by each individual surgery. |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Bilateral endometrioma
- Surgical endometriosis resection is planned
- sAMH > 1.0 ng/ml
Key exclusion criteria (4 listed)
- History of malignant diseases
- History of adnexal surgery
- Subject is unable or unwilling to participate
- Postmenopausal women
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| robotic-assisted laparoscopyAlso: DaVinci laparoscopySuperficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. Cystoscopy will be performed when deemed appropriate by the surgeon. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon. | Procedure or surgery | robotic-assisted laparoscopy |
| Conventional laparoscopySuperficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. Cystoscopy will be performed when deemed appropriate by the surgeon. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon. | Procedure or surgery | conventional laparoscopy |
Primary outcome
Change in serum AMH (sAMH) from baseline to 6 months after the operation
Time frame: 6 months after the operation
postoperative sAMH (6 months after the operation) compared to preoperative sAMH
13 secondary outcomes
Change in antral follicle count (AFC) from baseline to 6 months after the operation
Time frame: 6 months after the operation
change in ovarian volume from baseline to 6 months after the operation
Time frame: 6 months after the operation
change in follicle-stimulating hormone (FSH) and luteinizing hormone (LH) from baseline to 6 months after the operation
Time frame: 6 months after the operation
rate of intraoperative adverse events
Time frame: 1 day
rate of postoperative adverse events
Time frame: 4 weeks
operation time
Time frame: 1 day
length of hospitalization (following the operation)
Time frame: 2 weeks
blood loss
Time frame: 1 day
laparotomic conversion rate
Time frame: 1 day
follicle number in the histologic tissue sections
Time frame: 1 day
change of the Endometriosis Health Profile (EHP) EHP-30 from baseline to 6 months after the operation
Time frame: 6 months after the operation
10-point Likert scale for cosmetic satisfaction
Time frame: 6 months after the operation
Disease recurrence rate up to 12 months after surgery
Time frame: 12 months after the operation
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jun 2022.
- Individual participant dataSharing planned: No
Related trials for Ovarian Endometrioma
RecruitingPhase 4
Estetrol/Drospirenone to Reduce the Average Size of Endometriomas
Ovarian Endometrioma, Endometrioma
Recruiting
Effect of Alcohol Sclerotherapy on Pelvic Pain and Quality of Life in Women With Ovarian Endometriosis
Endometrioma, Ultrasound Therapy; Complications
Recruiting
Argon Plasma Treatment for Ovarian Endometrioma Compared to Standard Cystectomy
Endometriosis
RecruitingObservational study
Study on the Ultrasound and Biological Characteristics of Atypical Endometriosis.
Endometriosis
Not yet recruitingObservational study
Laparoscopic Sclerotherapy for the Management of Ovarian Endometriomas
Endometriosis, Endometrioma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Rene Wenzl study director
Medical University of Vienna, Department of Obstetrics and Gynecology
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing robotic-assisted laparoscopy and Conventional laparoscopy in people with Ovarian Endometrioma and Ovarian Endometriosis, run by Medical University of Vienna at 1 site in Austria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 8 Jun 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Austria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Christine Bekos (004369913536030, christine.bekos@meduniwien.ac.at), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in serum AMH (sAMH) from baseline to 6 months after the operation (time frame: 6 months after the operation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jun 2022.